About Us

Rich Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of its lead product, TPA (12-O- tetradecanoyl- phorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of the work of two scientists, Prof. Richard Chang and Prof. Zhang Tao Han. Both have conducted research on TPA for many years and have become experts in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. » Read more about us

Latest News

April 17

Rich Pharmaceuticals Appoints Professor Richard L. Chang to Medical Advisory Board View Release

April 14

Rich Pharmaceuticals Warns Investors of Unauthorized Spam Stock Promotion View Release

April 8

Rich Pharmaceuticals Appoints Renping Zhou, Ph.D., to Medical Advisory Board View Release

» Read Latest News